Hypoxia plays a crucial role in tumor biology and influences cancer progression, treatment resistance and patient prognosis [1]. Several fluorinated tracers bearing the nitroimidazole group have been developed for PET hypoxia imaging during recent years [2].
[18F]fluoroimidazole remains the most commonly used PET hypoxia tracer, although the second generation tracer, [18F]FAZA, has more favourable hydrophilicity and can improve signal-to-noise ratio. The [18F]FAZA precursor and reference standard are available from ABX. [1] KgomotsoM.GMokoala et al. Non-FDG hypoxia tracers. Semin. Nucl. Med. 2024, 54, 827-844. [2] Yuan Huang et al. Imaging of Tumor Hypoxia With Radionuclide-Labeled Tracers for PET. Front. Oncol. 2021, 11, 731503.
Learn more about this compound and send us your quote request:
ABX advanced biochemical compounds is a global frontrunner in radiopharmaceuticals, with a focus on positron emission tomography (PET) tracers. We develop and produce all compounds and components for any kind of radiotracer – from PET and SPECT precursors, PET reagent kits and cassettes, to complete radiopharmaceutical drug production in GMP environment.
Based in Radeberg, Germany, and founded in 1997, our team of about 400 employees is specialised in custom synthesis and manufacturing of precursors and peptides according to GMP for active pharmaceutical ingredients. Thanks to our expertise combined with bleeding edge equipment, we reach highest research, production, and quality standards.
ABX is the only service provider of radiopharmaceutical production with a complete and independent supply chain – from precursor or peptide to excipients and sterile disposables.
